Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18905502 | GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS | October 2024 | February 2025 | Allow | 5 | 1 | 0 | No | No |
| 18905534 | GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS | October 2024 | April 2025 | Allow | 6 | 1 | 0 | No | No |
| 18905520 | GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS | October 2024 | April 2025 | Allow | 7 | 1 | 0 | No | No |
| 18895044 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | September 2024 | March 2025 | Allow | 5 | 0 | 0 | No | No |
| 18892179 | Electronic Inhalation Device | September 2024 | February 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18745002 | INHIBITION OF CRYSTAL GROWTH OF ROFLUMILAST | June 2024 | February 2025 | Allow | 8 | 1 | 0 | No | No |
| 18653662 | TOPICAL ROFLUMILAST FORMULATION HAVING IMPROVED DELIVERY AND PLASMA HALF- LIFE | May 2024 | March 2025 | Allow | 10 | 1 | 0 | No | No |
| 18594194 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | March 2024 | March 2025 | Allow | 12 | 1 | 1 | No | No |
| 18594172 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | March 2024 | November 2024 | Allow | 8 | 1 | 0 | No | No |
| 18592262 | USE OF S-BETA-HYDROXYBUTYRATE COMPOUNDS FOR INDUCTION AND MAINTENANCE OF FLOW | February 2024 | February 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18589688 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | February 2024 | February 2025 | Allow | 11 | 1 | 1 | No | No |
| 18589636 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | February 2024 | November 2024 | Allow | 9 | 1 | 0 | No | No |
| 18432492 | GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX AND SEIZURE DISORDERS | February 2024 | September 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18429417 | METHODS OF REDUCING THE PRODUCTION OF GREENHOUSE GASES FROM ANIMALS | January 2024 | November 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18400944 | ETHYL [4,4-BIS(4-BROMOPHENYL)-2,5-DIOXOIMIDAZOLIDIN-1-YL]ACETATE AS AN ANTIMICROBIAL COMPOUND | December 2023 | April 2024 | Allow | 3 | 0 | 0 | No | No |
| 18540651 | METHODS OF TREATING CANCER WITH DRUGS | December 2023 | July 2024 | Allow | 7 | 1 | 0 | No | No |
| 18509800 | COMPOSITIONS AND METHODS FOR TREATING EYES AND METHODS OF PREPARATION | November 2023 | January 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18388707 | BENZOFURO[3,2-C]CHROMEN-6-ONE COMPOUNDS AS ANTIBACTERIAL AGENTS | November 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18385043 | 8-(3-FLUROBENZYLIDENEAMINO)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUND | October 2023 | February 2024 | Allow | 4 | 0 | 0 | No | No |
| 18496822 | 8-(2-HYDROXYBENZYLIDENEAMINO)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUND | October 2023 | January 2024 | Allow | 2 | 0 | 0 | No | No |
| 18493178 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | October 2023 | June 2024 | Allow | 8 | 2 | 0 | Yes | No |
| 18489542 | LOMITAPIDE FOR USE IN METHODS OF TREATING HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA IN PEDIATRIC PATIENTS | October 2023 | June 2025 | Allow | 20 | 3 | 0 | Yes | No |
| 18486888 | 3,4-DIMETHOXY-N'-(2-(5-PHENYL-1,3,4-OXADIAZOL-2YLTHIO)ACETOXY)BENZIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18371110 | 3-CYANO 4,5-DIPHENYL FURAN-2-CARBOXAMIDES AS ANTITUBERCULAR AGENTS | September 2023 | March 2024 | Allow | 5 | 2 | 0 | No | No |
| 18465446 | INHIBITION OF CRYSTAL GROWTH OF ROFLUMILAST | September 2023 | November 2023 | Allow | 2 | 1 | 0 | No | No |
| 18461389 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | September 2023 | May 2024 | Allow | 9 | 1 | 0 | No | No |
| 18242208 | 9-FLOURO-DIBENZO[B,G]INDENO[1',2':3,4]FLUORENO-[1,2-D]OXONINE-5, 11, 16,21-TETRAONE AS AN ANTIMICROBIAL AGENT | September 2023 | November 2023 | Allow | 2 | 0 | 0 | No | No |
| 18238292 | BENZOFURO[3,2-C]CHROMEN-6-ONE COMPOUNDS AS ANTIBACTERIAL AGENTS | August 2023 | July 2024 | Allow | 11 | 4 | 1 | No | No |
| 18237036 | 4-AMINO-5-(4-FLUORO-3-PHENOXYPHENYL)-4H-1,2,4-TRIAZOLE-3-THIOL DERIVATIVES AS ANTIFUNGAL AGENTS | August 2023 | January 2024 | Allow | 5 | 1 | 0 | No | No |
| 18453674 | Roflumilast Formulations with an Improved Pharmacokinetic Profile | August 2023 | May 2024 | Allow | 8 | 1 | 0 | No | No |
| 18233031 | SUBSTITUTED S-ALANINATE DERIVATIVES | August 2023 | October 2023 | Allow | 2 | 0 | 0 | No | No |
| 18215731 | Treatment of a Senescence-Associated Ocular Disease or Disorder Using a Bcl-xL Selective Inhibitor | August 2023 | January 2025 | Allow | 18 | 2 | 0 | Yes | No |
| 18353869 | TOPICAL ROFLUMILAST FORMULATION HAVING IMPROVED DELIVERY AND PLASMA HALF- LIFE | July 2023 | October 2023 | Allow | 3 | 1 | 0 | Yes | No |
| 18218519 | COMPOSITIONS CONTAINING S-BETA-HYDROXYBUTYRATE OR NON-RACEMIC MIXTURES ENRICHED WITH THE S-ENATIOMER | July 2023 | November 2023 | Allow | 5 | 1 | 0 | No | No |
| 18211816 | PROGESTERONE PHOSPHATE ANALOGS AND USES RELATED THERETO | June 2023 | May 2025 | Allow | 23 | 2 | 0 | Yes | No |
| 18141200 | HOMOLEPTIC METAL COORDINATION COMPLEXES AS ANTIFUNGAL AGENTS | April 2023 | August 2023 | Allow | 4 | 0 | 0 | No | No |
| 18300917 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | April 2023 | August 2024 | Abandon | 16 | 2 | 0 | No | No |
| 18300318 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | April 2023 | June 2024 | Abandon | 14 | 2 | 0 | No | No |
| 18192245 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | March 2023 | July 2023 | Allow | 4 | 0 | 0 | No | No |
| 18125959 | METHODS OF TREATING TUMORS WITH DRUGS | March 2023 | August 2023 | Allow | 5 | 1 | 0 | No | No |
| 18121359 | COMPOUNDED COMPOSITIONS AND METHODS FOR TREATING PAIN | March 2023 | January 2024 | Allow | 10 | 1 | 1 | No | No |
| 18176601 | TOPICAL ROFLUMILAST FORMULATION HAVING IMPROVED DELIVERY AND PLASMA HALF- LIFE | March 2023 | September 2023 | Allow | 6 | 2 | 0 | Yes | No |
| 18112621 | BENZOFURO[3,2-C]CHROMEN-6-ONE COMPOUNDS AS ANTIBACTERIAL AGENTS | February 2023 | August 2023 | Allow | 6 | 1 | 0 | No | No |
| 17920029 | GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONIST AND USE THEREOF | October 2022 | September 2023 | Allow | 11 | 1 | 0 | No | No |
| 17962976 | 1,2,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators | October 2022 | June 2025 | Allow | 32 | 0 | 0 | No | No |
| 17915192 | Carboxylate Ligand Modified Ferric Iron Hydroxide Compositions for use in the Treatment or Prevention of Iron Deficiency Associated with Liver Diseases | September 2022 | May 2025 | Allow | 31 | 0 | 0 | No | No |
| 17929633 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | September 2022 | June 2023 | Allow | 10 | 2 | 0 | No | No |
| 17929631 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | September 2022 | June 2023 | Allow | 10 | 2 | 0 | No | No |
| 17880925 | SRPK1 INHIBITORS | August 2022 | February 2025 | Allow | 30 | 1 | 1 | No | No |
| 17816812 | URSODEOXYCHOLIC ACID-CONTAINING AGENT FOR TREATING OR PREVENTING PRESBYOPIA | August 2022 | October 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17872450 | NOREPINEPHRINE COMPOSITIONS AND METHODS THEREFOR | July 2022 | February 2023 | Allow | 6 | 1 | 0 | No | No |
| 17871925 | CHELATED, STABLE OPHTHALMOLOGICAL COMPOSITIONS OF KETOROLAC AND PHENYLEPHRINE AND APPLICATIONS THEREOF | July 2022 | February 2024 | Allow | 19 | 4 | 1 | No | No |
| 17865745 | HIGH-PURITY MOGROSIDES AND PROCESS FOR THEIR PURIFICATION | July 2022 | May 2025 | Allow | 34 | 0 | 0 | No | No |
| 17861752 | NOREPINEPHRINE COMPOSITIONS AND METHODS THEREFOR | July 2022 | July 2024 | Allow | 25 | 1 | 1 | No | No |
| 17809151 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | June 2022 | April 2023 | Allow | 9 | 2 | 0 | No | No |
| 17845905 | COMPOSITIONS AND METHODS FOR REDUCING MUSCLE CONTRACTION | June 2022 | January 2025 | Allow | 30 | 2 | 1 | No | No |
| 17740109 | METHOD FOR REDUCING OTOTOXICITY IN PEDIATRIC PATIENTS RECEIVING PLATINUM-BASED CHEMOTHERAPY | May 2022 | August 2023 | Abandon | 16 | 1 | 1 | No | No |
| 17733868 | METHODS OF TREATING TUMORS WITH PRO DRUGS | April 2022 | December 2022 | Allow | 7 | 1 | 0 | Yes | No |
| 17730737 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | April 2022 | March 2025 | Allow | 34 | 1 | 0 | No | No |
| 17731247 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | April 2022 | February 2023 | Allow | 10 | 1 | 0 | No | No |
| 17660673 | METHODS FOR TREATING LIVER DISORDERS USING FXR AGONISTS | April 2022 | March 2025 | Abandon | 35 | 1 | 0 | No | No |
| 17728600 | KETONE BODIES AND KETONE BODY ESTERS AS BLOOD LIPID LOWERING AGENTS | April 2022 | July 2025 | Allow | 38 | 1 | 0 | No | No |
| 17728554 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | April 2022 | February 2023 | Allow | 10 | 1 | 0 | No | No |
| 17769774 | EXPECTORANT COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF | April 2022 | March 2024 | Allow | 23 | 0 | 0 | No | No |
| 17723050 | COMPOSITIONS AND METHODS FOR TREATING EYES AND METHODS OF PREPARATION | April 2022 | January 2025 | Abandon | 33 | 0 | 1 | No | No |
| 17712274 | PARENTERAL UNIT DOSAGE FORM OF DIHYDROERGOTAMINE | April 2022 | February 2023 | Allow | 10 | 2 | 1 | No | No |
| 17707913 | HOMOGENEOUS OPHTHALMIC COMPOSITION | March 2022 | June 2025 | Allow | 39 | 4 | 1 | No | No |
| 17707784 | METHOD FOR PREVENTING AND/OR TREATING CHRONIC TRAUMATIC ENCEPHALOPATHY-I | March 2022 | May 2025 | Allow | 38 | 2 | 0 | No | No |
| 17692068 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | March 2022 | June 2023 | Allow | 15 | 2 | 0 | No | No |
| 17690321 | METHOD AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION | March 2022 | August 2023 | Allow | 17 | 1 | 0 | No | No |
| 17689245 | ORAL CANNABINOID FORMULATIONS | March 2022 | October 2023 | Allow | 19 | 1 | 0 | No | No |
| 17689704 | METHODS OF TREATING CANCER | March 2022 | September 2024 | Allow | 30 | 1 | 1 | No | No |
| 17653540 | HPK1 ANTAGONISTS AND USES THEREOF | March 2022 | October 2023 | Allow | 19 | 1 | 1 | No | No |
| 17687485 | OMEGA-3 FATTY ACID SUPPLEMENTATION FOR USE IN TREATING DRY EYE | March 2022 | January 2023 | Allow | 10 | 2 | 0 | Yes | No |
| 17677906 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | February 2022 | December 2022 | Allow | 10 | 2 | 0 | No | No |
| 17651023 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | February 2022 | December 2022 | Allow | 10 | 1 | 1 | No | No |
| 17651029 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | February 2022 | December 2022 | Allow | 10 | 1 | 1 | No | No |
| 17651038 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | February 2022 | November 2022 | Allow | 9 | 1 | 0 | No | No |
| 17651017 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | February 2022 | November 2022 | Allow | 9 | 1 | 1 | No | No |
| 17632973 | Methods And Compositions For The Treatment Of Hair Loss | February 2022 | October 2024 | Allow | 33 | 1 | 1 | No | No |
| 17591543 | APPLICATIONS FOR ESTRADIOL IN PREPARING ANTI-SMALL CELL LUNG CANCER AND/OR OVARIAN CANCER AND/OR OSTEOSARCOMA PRODUCTS | February 2022 | May 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17597917 | PREPARATION METHOD AND USE OF PYRAZOLE COMPOUND CONTAINING 1-(3,4-DIMETHOXYPHENYL)-BETA-CARBOLINE UNIT | January 2022 | May 2025 | Allow | 40 | 1 | 0 | No | No |
| 17580755 | Compositions and Methods for the Prevention and Treatment of Hearing Loss | January 2022 | June 2022 | Allow | 5 | 2 | 1 | No | No |
| 17573878 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | January 2022 | April 2022 | Allow | 3 | 1 | 0 | No | No |
| 17574272 | DIHYDROPYRIDINE COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | January 2022 | August 2023 | Allow | 19 | 1 | 0 | No | No |
| 17626074 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | January 2022 | February 2025 | Allow | 38 | 0 | 0 | Yes | No |
| 17555724 | KETONE BODY ESTERS OF S-BETA-HYDROXYBUTYRATE AND/OR S-1,3-BUTANEDIOL FOR MODIFYING METABOLIC FUNCTION | December 2021 | June 2023 | Allow | 18 | 1 | 0 | No | No |
| 17644914 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | December 2021 | October 2022 | Allow | 10 | 1 | 1 | No | No |
| 17644907 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | December 2021 | March 2022 | Allow | 3 | 1 | 0 | Yes | No |
| 17550669 | FULVESTRANT FORMULATIONS | December 2021 | October 2024 | Abandon | 34 | 1 | 1 | No | No |
| 17549081 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | December 2021 | May 2022 | Allow | 5 | 1 | 0 | No | No |
| 17549475 | TARGETING HYPOXIC CANCER STEM CELLS (CSCS) WITH DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY | December 2021 | November 2024 | Abandon | 35 | 2 | 1 | No | No |
| 17548004 | TREATMENT OF PARKINSON'S DISEASE AND OTHER CONDITIONS CAUSED OR MEDIATED BY SENESCENT ASTROCYTES USING SMALL MOLECULE SENOLYTIC AGENTS | December 2021 | February 2024 | Abandon | 26 | 2 | 1 | No | No |
| 17546895 | URSODEOXYCHOLIC ACID-CONTAINING AGENT FOR TREATING OR PREVENTING PRESBYOPIA | December 2021 | May 2022 | Allow | 5 | 1 | 0 | Yes | No |
| 17544365 | PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM | December 2021 | May 2022 | Allow | 5 | 1 | 0 | No | No |
| 17535559 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING ADHESIONS AND ILUES | November 2021 | August 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17534951 | FXR (NR1H4) MODULATING COMPOUNDS | November 2021 | August 2024 | Abandon | 32 | 2 | 0 | No | No |
| 17525573 | EXTRACT, CONSUMABLE PRODUCT AND METHOD FOR ENRICHING BIOACTIVE METABOLITE IN AN EXTRACT | November 2021 | March 2023 | Allow | 16 | 1 | 1 | No | No |
| 17516556 | CARBAZOLE DERIVATIVES FOR THE TREATMENT OF FIBROTIC DISEASES AND RELATED SYMPTOMS, AND CONDITIONS THEREOF | November 2021 | May 2024 | Allow | 31 | 1 | 1 | No | No |
| 17603876 | BIFUNCTIONAL COMPOUNDS COMPRISING APCIN-A AND THEIR USE IN THE TREATMENT OF CANCER | October 2021 | May 2025 | Allow | 43 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HOWELL, THEODORE R..
With a 13.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner HOWELL, THEODORE R. works in Art Unit 1628 and has examined 1,097 patent applications in our dataset. With an allowance rate of 64.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 27 months.
Examiner HOWELL, THEODORE R.'s allowance rate of 64.4% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by HOWELL, THEODORE R. receive 1.88 office actions before reaching final disposition. This places the examiner in the 59% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by HOWELL, THEODORE R. is 27 months. This places the examiner in the 55% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +28.1% benefit to allowance rate for applications examined by HOWELL, THEODORE R.. This interview benefit is in the 79% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.8% of applications are subsequently allowed. This success rate is in the 24% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 43.8% of cases where such amendments are filed. This entry rate is in the 61% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 73.7% of appeals filed. This is in the 58% percentile among all examiners. Of these withdrawals, 66.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 46.8% are granted (fully or in part). This grant rate is in the 54% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.6% of allowed cases (in the 63% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.4% of allowed cases (in the 80% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.